SIMCERE PHARMAC. GRP LTD
Research SIMCERE PHARMAC. GRP LTD (S2P) on Bullrun: market cap EUR 3.31B, P/E 18.4, dividend yield 1.9%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerS2P
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 3.31B
- P/E18.4
- Dividend yield1.9%
- Financial periodFY2025
- RevenueCNY 7.73B
- Revenue growth16.5%
- Net incomeCNY 1.34B
- Free cash flowCNY 1.15B
- Gross margin81.6%
Valuation Snapshot
latest market cap is EUR 3.31B; P/E is 18.4; dividend yield is 1.9%.
Peer valuation comparison
Latest P/E is 18.43x versus a Healthcare sector median of 24.46x (24.7% below).
Latest dividend yield is 1.9% versus a Healthcare sector median of 2.11% (10.0% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 7.73B | CNY 1.34B | CNY 1.15B | 81.6% | 0.54 | CNY 3.51B | CNY 1.19B | CNY 9.41B |
| FY2024 | CNY 6.64B | CNY 733.17M | CNY 628.54M | 80.2% | 0.29 | CNY 1.94B | CNY 1.21B | CNY 7.07B |
| FY2023 | CNY 6.61B | CNY 714.76M | -CNY 828.81M | 75.4% | 0.27 | CNY 2.01B | CNY 1.43B | CNY 7.22B |
| FY2022 | CNY 6.32B | CNY 930.87M | CNY 676.09M | 79.0% | 0.36 | CNY 1.66B | CNY 1.51B | CNY 7.13B |
| FY2021 | CNY 5.00B | CNY 1.51B | -CNY 411.46M | 78.4% | 0.58 | CNY 973.14M | CNY 1.64B | CNY 6.44B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 3.31B | 18.4 | 1.8% | 0.02 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.02 EUR, yield 1.9%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.02 CNY |
| FY2024 | 0.02 CNY |
| FY2023 | 0.02 CNY |
| FY2022 | 0.02 CNY |
| FY2021 | 0.02 CNY |
About SIMCERE PHARMAC. GRP LTD
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SIMCERE PHARMAC. GRP LTD's market cap?
SIMCERE PHARMAC. GRP LTD's market capitalization is EUR 3.31B.
What is SIMCERE PHARMAC. GRP LTD's P/E ratio?
SIMCERE PHARMAC. GRP LTD's price-to-earnings (P/E) ratio is 18.4.
Does SIMCERE PHARMAC. GRP LTD pay a dividend?
SIMCERE PHARMAC. GRP LTD has a dividend yield of 1.9%.
What does SIMCERE PHARMAC. GRP LTD do?
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clinical trials.